Investors

Press Releases

Press Releases

September 19, 2022
SAN CARLOS, Calif. , Sept. 19, 2022 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) and AK006 for the treatment of allergic and inflammatory diseases, today announced the pricing of an underwritten offering of 29,882,000 shares of its common
February 1, 2022
– Management will discuss lirentelimab development and Allakos pipeline – REDWOOD CITY, Calif. , Feb. 01, 2022 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company” or “Allakos”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related

Data Provided by Refinitiv. Minimum 15 minutes delayed.